Patents by Inventor Scott Novick
Scott Novick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11914782Abstract: In some implementations, a computing device can be configured to automatically turn off notifications when generating a notification would cause a disturbance or be unwanted by a user. The device can be configured with quiet hours during which notifications that would otherwise be generated by the computing device can be suppressed. In some implementations, quiet hours can be configured as a time period with a start time and an end time. In some implementations, quiet hours can be derived from application data. For example, calendar data, alarm clock data, map data, etc. can be used to determine when quiet hours should be enforced. In some implementations, the device can be configured with exceptions to quiet hour notification suppression. In some implementations, the user can identify contacts to which the quiet hours notification suppression should not be applied.Type: GrantFiled: February 10, 2023Date of Patent: February 27, 2024Assignee: Apple Inc.Inventors: Imran A. Chaudhri, Gregory Novick, Scott Forstall, Morgan Grainger, George R. Dicker, Tyler Hawkins
-
Patent number: 9963683Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: GrantFiled: February 15, 2017Date of Patent: May 8, 2018Assignee: Codexis, Inc.Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Publication number: 20170159028Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: ApplicationFiled: February 15, 2017Publication date: June 8, 2017Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Patent number: 9605290Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: GrantFiled: May 10, 2016Date of Patent: March 28, 2017Assignee: Codexis, Inc.Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Publication number: 20160244792Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: ApplicationFiled: May 10, 2016Publication date: August 25, 2016Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Patent number: 9365878Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: GrantFiled: July 2, 2015Date of Patent: June 14, 2016Assignee: Codexis, Inc.Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Patent number: 9193957Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: GrantFiled: May 9, 2013Date of Patent: November 24, 2015Assignee: Codexis, Inc.Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt Huisman, Scott Novick, Nicholas Agard, Oscar Alvizo, Gregory Cope, Wan Lin Yeo, Stefanie Ng Minor
-
Publication number: 20150329835Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: ApplicationFiled: July 2, 2015Publication date: November 19, 2015Inventors: Anupam Gohel, Derek J. Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Patent number: 9102963Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: GrantFiled: April 12, 2012Date of Patent: August 11, 2015Assignee: Codexis, Inc.Inventors: Anupam Gohel, Derek Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Patent number: 8932836Abstract: The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.Type: GrantFiled: August 8, 2011Date of Patent: January 13, 2015Assignee: Codexis, Inc.Inventors: John Limanto, Gregory Beutner, Brendan Grau, Jacob Janey, Artis Klapars, Eric R. Ashley, Hallena R. Strotman, Matthew D. Truppo, Gregory Hughes, Fabien Cabirol, Anupam Gohel, Steven J. Collier, Jack Liang, Marissa Mock, Emily Mundorff, Scott Novick, Derek Smith
-
Publication number: 20140199735Abstract: The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.Type: ApplicationFiled: April 12, 2012Publication date: July 17, 2014Applicant: CODEXIS, INC.Inventors: Anupam Gohel, Derek Smith, Brian Wong, Joly Sukumaran, Wan Lin Yeo, Steven J. Collier, Scott Novick
-
Publication number: 20130302859Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: CODEXIS,INC.Inventors: CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
-
Publication number: 20130164794Abstract: The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.Type: ApplicationFiled: August 8, 2011Publication date: June 27, 2013Applicant: CODEXIS, INC.Inventors: John Limanto, Gregory Beutner, Brendan Grau, Jacob Janey, Artis Klapars, Eric Ashley, Hallena R. Strotman, Matthew D. Truppo, Gregory Hughes, Fabien L. Cabirol, Anupam Gohel, Steven J. Collier, Jack Liang, Marissa Mock, Emily Mundorff, Scott Novick, Derek Smith
-
Patent number: 8420364Abstract: The present disclosure relates to ?-class carbonic anhydrase polypeptides having improved properties including increased thermostability and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides formulations and uses of the polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering. Also provided are polynucleotides encoding the carbonic anhydrase polypeptides and host cells capable of expressing them.Type: GrantFiled: June 30, 2011Date of Patent: April 16, 2013Assignee: Codexis, Inc.Inventors: Oscar Alvizo, Mike Benoit, Scott Novick
-
Patent number: 8354261Abstract: The present disclosure relates to ?-class carbonic anhydrase polypeptides having improved properties including increased thermostability and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides formulations and uses of the polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering. Also provided are polynucleotides encoding the carbonic anhydrase polypeptides and host cells capable of expressing them.Type: GrantFiled: June 30, 2011Date of Patent: January 15, 2013Assignee: Codexis, Inc.Inventors: Oscar Alvizo, Mike Benoit, Irene Fusman, Jack Liang, Luan Nguyen, Scott Novick
-
Patent number: 8354262Abstract: The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering.Type: GrantFiled: June 30, 2011Date of Patent: January 15, 2013Assignee: Codexis, Inc.Inventors: Scott Novick, Oscar Alvizo
-
Publication number: 20120009646Abstract: The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering.Type: ApplicationFiled: June 30, 2011Publication date: January 12, 2012Applicant: CODEXIS, INC.Inventors: Scott Novick, Oscar Alvizo
-
Publication number: 20040115691Abstract: Mutants of leucine dehydrogenase sequences, formate dehydrogenase sequences and galactose oxidase sequences are provided. An amino acid sequence that is a mutant of a leucine dehydrogenase sequence as described in SEQ ID 2, or its substantial equivalent, contains at least one mutation selected from the group consisting of F102S, V33A, S351T, N145S and like mutations in subsantially equivalent sequences. An amino acid sequence that is a mutant of a formate dehydrogenase sequence as described in SEQ ID 1, or its substantial equivalent, contains at least one mutation selected from the group consisting of D195S, Y196H, K356T and like mutations in subsantially equivalent sequences.Type: ApplicationFiled: July 10, 2003Publication date: June 17, 2004Inventors: J. David Rozzell, Ling Hua, Martin Mayhew, Scott Novick